Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
APTAMER TECHNOLOGY - From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers November 30, 2021
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
SOTIO Expands Its Antibody-Drug Conjugate Pipeline With Exclusive Collaboration & License Agreement With LegoChem Biosciences November 16, 2021
SOTIO Biotech recently announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc in which SOTIO will obtain rights to deploy LCB’s ADC technology for up to….
Trio Pharmaceuticals & Ajinomoto Bio-Pharma Services Enter Development Collaboration for a Novel Antibody Therapeutic April 29, 2020
Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services recently announced a development collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by…
Femtogenix Presents Novel Data on Antibody Drug Conjugates October 29, 2019
Femtogenix Ltd recently announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analogue from its...Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases September 23, 2019
Now, the power of nucleic acid technology is being harnessed to design small molecule nucleic acid hybrid (SMNH) drugs that harness the patient’s own immune system to defeat…..
BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration April 9, 2019
BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial February 21, 2019
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability,...SPECIAL FEATURE - Outsourcing Analytical Testing: The Gateway to Drug Manufacturing January 10, 2019
Contributor Cindy H. Dubin speaks with several leading analytical labs and CDMOs to review their technologies, services, and new strategies to operate in this ever-changing environment.
Ajinomoto Bio-Pharma Services Introduces Bioconjugation Technology for ADC Manufacturing November 28, 2018
Ajinomoto Bio-Pharma Services recently presented data at the World ADC Summit in San Diego this month describing a proprietary site-selective bioconjugation technology, AJICAP.
ANTIBODY DRUG CONJUGATES - Expansion of Approved Indications Backs 25% Increase in Global Market October 1, 2018
Laurie L. Sullivan and Shalini Shahani Dewan, MS, believe technological advancements, the rising incidence of cancer, and an increasing demand for biologic therapies are all factors driving growth in the global ADC market.
INJECTABLE NANOMEDICINES - New Developments in Long-Acting Injectable Nanoformulations May 22, 2018
Dongwei Guo, PhD, and Jingjun Huang, PhD, focus on the overview of nanoproducts in the market and the technologies to make long-acting injectable nanoformulations.
MONOCLONAL ANTIBODIES - The Development of Therapeutic Monoclonal Antibody Products: A Comprehensive Guide to CMC Activities From Clone to Clinic April 3, 2018
Howard L. Levine, PhD, and Brendan R. Cooney, provide a guide to product development companies, service providers, investors, and analyst as they work their way through the complex and rapidly evolving world of therapeutic monoclonal antibodies.
Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development November 30, 2017
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag®...Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency & Antibody Drug Conjugate Commercial Facility September 25, 2017
Ajinomoto Althea, Inc. recently announced it will soon open a GMP production suite in its newly constructed High Potency Products...SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
MilliporeSigma Offers Fully Integrated ADC Services to Reduce Complexity, Accelerate Time to Market February 28, 2017
MilliporeSigma recently announced it now offers complete and fully integrated services and products for the development and manufacturing of antibody-drug...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Using a Single Provider Reduces Costs & Risk March 30, 2016
Contributor Cindy H. Dubin highlights several CDMOs that are evolving their models to become their clients’ single provider and to accommodate their more potent, challenging products.
Ajinomoto Althea Launches Process & Analytical Development Services for ADC Therapeutics December 10, 2015
Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing...Ajinomoto Althea Expands Manufacturing Capabilities to ADC Fill Finish & Bioconjugation October 16, 2015
Ajinomoto Althea, Inc. recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials...
